More diabetes wins are in the news this week. Dexcom announced that its G6 continuous glucose monitor won expanded coverage in Canada. Fast Five hosts Sean Whooley and Danielle Kirsh discuss how the indication could expand access to the diabetes management technology to underserved communities.

Innoblative Designs won FDA breakthrough designation this week for its ablation device that is indicated for breast cancer surgery. Whooley details how the device works and how the company anticipates it to streamline procedures and workflows.

It's not your average bandage. Kirsh and Whooley discuss the technology behind 3M's latest Veraflo therapy dressings that recently received FDA clearance. The Fast Five hosts also provide insight from surgeons who are ready to use the dressings.

Spinal cord stimulation could be used to treat diabetes complications – that's what Nevro hopes with its latest PDN Sensory study. Kirsh and Whooley provide more details about the clinical trial and what benefits could come with this new treatment method.

Earnings season continues with Baxter's latest Q1 report that beat estimates on Wall Street. It raised its guidance for the remainder of the year, as well. Whooley explains how the company performed and the optimism Baxter's CEO has for the remainder of the year.

Check out the show notes at massdevice.com/podcast.